Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia.
Louis. Pasteur University Hospital, Košice, Slovakia.
Pharmacogenomics. 2020 Apr;21(5):317-323. doi: 10.2217/pgs-2019-0147. Epub 2020 Apr 20.
We examined associations of eight SNPs in/near seven candidate genes with glycemic response to 6 month treatment with DPP4 inhibitors. 206 patients with type 2 diabetes (116 men and 90 women) were treated with sitagliptin or vildagliptin (both 100 mg/day) in combination with metformin or metformin/sulphonylurea over 6 months, and the reduction in glycated hemoglobin (HbA) was measured. Rs6923761 in was significantly associated with a reduction in HbA (adjusted p = 0.006). Homozygotes for the minor A allele had smaller reduction in HbA by 0.4% (4 mmol/mol) than the G allele carriers (p = 0.016). The missense variant rs6923761 in the gene was associated with a smaller glycemic response to 6 month gliptin therapy in diabetic patients of central European origin.
我们研究了 7 个候选基因中的 8 个 SNP 与 DPP4 抑制剂治疗 6 个月后血糖反应的相关性。206 例 2 型糖尿病患者（男性 116 例，女性 90 例）接受西格列汀或维格列汀（均为 100mg/天）联合二甲双胍或二甲双胍/磺脲类药物治疗 6 个月，测量糖化血红蛋白（HbA）的降低情况。位于 中的 rs6923761 与 HbA 的降低显著相关（调整后的 p = 0.006）。与 G 等位基因携带者相比，A 等位基因纯合子的 HbA 降低幅度小 0.4%（4mmol/mol）（p = 0.016）。位于 基因中的错义变异 rs6923761 与中欧裔糖尿病患者接受 6 个月gliptin 治疗后的血糖反应较小相关。
